Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2618960 in Primary Sjögren's Syndrome
NCT03239600Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Sep 2017
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing GSK2618960 + MTX with Placebo + MTX (2 arms). Primary endpoints: Number of subjects with Adverse Events, Number of subjects with abnormal clinical chemistry values and 4 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
GSK2618960
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT03239600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239600.